ABSTRACT
Conclusion:
Our study showed that SF-A levels were not changed in patients with AA amyloidosis. Also, SF-A levels and carotid IMT were not associated in patients with AA amyloidosis.
Results:
We determined a significant increase in carotid IMT among patients with AA amyloidosis compared to healthy controls (p<0.001). SF-A levels were similar in patients and controls (p=0.11). In addition, we did not find any correlation between SF-A levels and carotid IMT (r=0.074, p=0.565).
Methods:
We recruited 63 patients with AA amyloidosis and 29 age-matched healthy controls. Demographic data, biochemical parameters, SF-A and carotid IMT values between two groups were compared. We also investigated the association between carotid IMT and SF-A levels in patients with AA amyloidosis.
Objective:
Amyloidosis is the build-up of amyloid fibrils in tissues, which eventually leads to various local and systemic problems. Amyloid A amyloidosis (AA amyloidosis) is the most frequent type of systemic amyloidoses. Data from cohort studies show that decreased serum fetuin-A (SF-A) levels in the serum are associated with morbidity and mortality in patients with end-stage kidney disease. Our aim was to investigate whether elevated SF-A levels were associated with common carotid intima-media thickness (IMT) in patients with AA amyloidosis.
INTRODUCTION
Amyloidosis is characterized by the accumulation of abnormal fibril proteins which leads various local and systemic diseases. The amyloid fibrils are usually comprised of mutant, fragmented and altered proteins with abnormal conformation.
On the global scale, amyloid A (AA) amyloidosis is reportedly the most frequently diagnosed form of amyloidosis. It is especially frequent in the developing countries, which is considered to be due to higher frequency of associated infections. Proteinuria and/or impaired renal function, which may progress to chronic renal failure, is known to develop in patients with AA amyloidosis (1). In patients with end-stage renal disease, arterial stiffness has been reported to be independently associated with all-cause cardiovascular mortality and morbidity (2,3). Clinical and subclinical atherosclerosis can be evaluated by the measurement of common carotid intima-media thickness (IMT) (2,4-6).
Human serum fetuin-A (SF-A) (also known as alpha-2 Heremans-Schmid glycoprotein) is an endogenous blood glycoprotein with inhibitory effects on cysteine proteases. It is secreted from the liver and has a role in systemic calcification. SF-A also functions in various metabolic pathways, including calcium homeostasis/bone development, phagocytosis and is suggested to contribute to insulin sensitivity (7-9). Some recent studies have demonstrated inverse relationships between SF-A levels and atherosclerosis (7,9,10). Several cohort studies focused on patients with end-stage renal disease have concluded that lower SF-A levels are associated with mortality and cardiovascular events (11).
To our knowledge, there are only a few studies that have investigated carotid IMT in patients with AA amyloidosis. Furthermore, we found no studies that investigated SF-A levels and carotid IMT in AA amyloidosis.
Our aim was to evaluate whether any relationship existed between subclinical atherosclerosis (carotid IMT) and SF-A levels in patients with AA amyloidosis.
METHOD
This study was performed on 63 patients with AA amyloidosis who attended their usual follow up studies between April 2018 and May 2018 at the Nephrology Department of İnternal Diseases. The control group was comprised of 29 aged-matched healthy subjects. The investigation was performed as an observational cross-sectional study. AA amyloidosis was diagnosed by means of biopsies from different tissues such as the kidney, gingiva, rectum, duodenum or bone marrow. Patients with diabetes mellitus, hypertension, liver diseases, hyperthyroidism, hypothyroidism, hematological disorders, malignancy and acute/chronic infections were excluded from the study.
Patients’ systolic and diastolic blood pressures (SBP and DBP, respectively) were measured with a sphygmomanometer while the patient was sitting after at least 5 minutes of rest. Body mass index (BMI) was calculated by dividing weight (kg) by the square of height (m2). The Chronic Kidney Disease Epidemiology Collaboration equations was used to calculate estimated glomerular filtration rate (eGFR) (12).
Plasma samples were aliquoted and stored at -80 °C until measurement. SF-A levels were measured with a human fetuin enzyme-linked immunosorbent assay kit (BioVendor Laboratory Medicine, Czech Republic) according to manufacturer instructions. Erythrocyte sedimentation rate (ESR), urea, creatinine, albumin, calcium, phosphate, C-reactive protein (CRP) and parathyroid hormone (PTH) levels were measured by the routine biochemistry laboratory via auto-analyzers.
Measurement of Carotid İntima-Media Thickness
Measurements of carotid IMT were performed with a 5-12 MHz superficial probe using an M-Turbo ultrasonography device (SonoSite Inc., Bothell, WA, USA). The carotid IMTs were measured from the classic site described by Pignoli et al. (13) (1 cm proximal to the bifurcation). The carotid IMT was defined as the distance between the media-adventitia and the lumen-intima interfaces. The final carotid IMT values of each patient was calculated as the mean of triplicate measurements of both carotid arteries.
The study was approved by İstanbul Medeniyet University Göztepe Training and Research Hospital Clinical Research Ethics Committee on April 10, 2018 (Protocol number: 2013-KAEK-64), and informed consents were taken from all participants.
Statistical Analysis
All data analysis was performed on Statistical Package for Social Sciences (SPSS) version 21.0 program for the Windows operating system (SPSS Inc., Chicago, USA). The normality of distribution of continuous variables were evaluated with the Shapiro-Wilk test. We analyzed descriptive statistics (medians and standard deviations) and performed 2-group comparisons with the students t-test or the Mann-Whitney U test depending on normality. Data were shown as median and interquartile range. The correlations in the study were evaluated by calculation of Spearman’s rho. P values lower than or equal to 0.05 were considered to show statistical significance.
RESULTS
A total of 63 patients with AA amyloidosis and 29 healthy controls were included in this study. The female/male distribution was 29 (55%)/34 (45%) in the amyloidosis group, and 21 (72%)/8 (28%) in control group. Statistical analysis revealed that sex distribution was different between groups (p=0.019). However, the groups were similar in terms of age, SBP and DBP. Patients with amyloidosis had significantly lower BMI than controls (p<0.001) (Table 1).
Urea, creatinine, phosphorus, CRP, ESR and PTH levels were significantly higher in amyloidosis patients compared to healthy controls (p<0.05, for each comparison). In contrast, serum albumin, calcium levels and eGFR were significantly lower in amyloidosis patients compared to healthy controls (p<0.001) (Table 1).
There was no significant difference between patients and controls in terms of SF-A levels (117.6±52.4 mmol/L vs. 119.9±23 mmol/L, respectively) (Table 1). However, we determined that SF-A levels among patients with an eGFR value lower than 30 mL/min/1.73 m2 were significantly lower than the SF-A levels of those with eGFR values between 30-60 mL/min/1.73 m2 (p=0.011).
Mean carotid IMT of those with AA amyloidosis (0.8±0.4 mm) was significantly higher compared to the mean carotid IMT of the control group (0.6±0.2 mm) (p<0.001) (Table 1). There was no relationship between SF-A levels and carotid IMT in our patient group (r=0.074, p=0.565) (Figure 1). Similarly, there was also no correlation between SF-A levels and eGFR values (r=0.186, p=0.144).
In patients with AA amyloidosis, a positive correlation was determined between serum calcium and SF-A levels (r=0.351, p=0.005) (Figure 2), and between serum albumin and SF-A levels (r=0.271, p=0.031). In addition, there was a negative correlation between serum PTH levels and SF-A levels in the patient group (r=0.325, p=0.019). The study showed no association between BMI, CRP, ESR, creatinine, urea, phosphate and SF-A values in the patient group.
DISCUSSION
Our study showed that the levels of ESR, CRP, urea, creatinine, phosphorus and PTH were increased in AA amyloidosis compared to controls; whereas serum albumin, calcium and eGFR were lower. In addition, we determined that the SF-A levels of AA amyloidosis patients with eGFR values under 30 mL/min/1.73 m2 were lower compared to the SF-A levels of AA amyloidosis patients whose eGFR values were between 30-60 mL/min/1.73 m2. Furthermore, we found that carotid IMT was increased patients with AA amyloidosis compared to controls. Lastly, in regard to correlation analyses, we found positive correlations between SF-A and the levels of serum calcium and serum albumin. Additionally, we also showed the existence of a negative correlation between serum PTH levels and SF-A levels.
To our knowledge, this is the first study to investigate the association between SF-A levels and different parameters affecting mineralization dynamics and subclinical atherosclerosis in AA amyloidosis patients. We found no association between higher levels of SF-A and AA amyloidosis.
A previous study investigated the vascular calcification process in patients with chronic renal failure. This study concluded that chronic renal failure is associated with the loss of inhibition of mineralization as well as an unbalanced calcium and phosphate homeostasis. The same study also indicated that SF-A had a role in the vascular calcification in recipients of hemodialysis (14).
Various studies have focused on SF-A levels in type 2 diabetes mellitus and chronic kidney disease (CKD). Several of these studies have shown that there is a strong association between SF-A levels and the risk for diabetes (15-19). Furthermore, SF-A levels were reportedly lower in patients with type 2 diabetes (20). While Sujana et al. (21) determined that higher SF-A levels were associated with incident type 2 diabetes in both genders, regardless of the presence of subclinical inflammation, the levels of adiponectin, and fat content of the liver. Despite many other studies indicating a role for SF-A in diabetes, a recent systematic review found that the relationship between diabetes and SF-A was only evident in females; the authors also concluded that further studies were required to understand the underlying cause of this relationship (22).
Siraz et al. showed that patients with non-alcoholic fatty liver disease (NAFLD) had elevated SF-A levels. They identified a SF-A cut-off to predict NAFLD presence; however, while specificity was quite high (97%), sensitivity was as low as 47%. The authors also suggested that SF-A was a reliable parameter for the prediction of complications in patients with type 1 diabetes mellitus (23). These findings show that SF-A may have a role in various diseases due to its role in metabolic pathways.
In a study which investigated basal ganglia calcification, by Demiryurek et al. (24), it was determined that SF-A levels were lower in patients with basal ganglia calcification compared to subjects without calcification. They suggested that SF-A level may be used as a biomarker in the prediction of basal ganglia calcification (24).
A few studies have investigated whether there exists a relationship between carotid IMT and SF-A levels. In essential hypertension patients, higher SF-A levels were associated with increased IMT, independent of oxidative stress and renal function (25). Liang et al. (26) showed a negative correlation between SF-A level and carotid IMT. They also concluded that lower SF-A level was a risk factor for carotid artery calcification in patients with CKD. In the current study, we found no relationship between carotid IMT values and the levels of SF-A in our group of patients with AA amyloidosis (r=0.074, p=0.565), (Figure 1). Furthermore, our study showed that the carotid IMT of patients with AA amyloidosis were statistically higher than that of controls (p<0.001) (Table 1).
There are also studies in which SF-A levels were investigated in patients with CKD. Caglar et al. (27) found that SF-A concentrations were decreased at all stages of CKD except stage 1. They also showed that endothelial dysfunction was associated with SF-A, regardless of CKD. Hence, they concluded that SF-A may be a factor that contributes to the development of endothelial dysfunction in CKD patients (28). In contrast, Alderson et al. (29) reported that there was no clear association between SF-A levels and any risk factors associated with renal replacement therapy, cardiovascular events and death in non-dialysis patients with stage 3-5 CKD.
Dervisoglu et al. (30) found that higher serum SF-A levels were associated with lower interleukin (IL)-1β, IL-6 and tumor necrosis factor-α levels in their group of 64 patients with CKD. They concluded that the inverse relationship between SF-A and cytokine levels was associated with the down-regulation of SF-A expression during inflammation. In the present study, we showed that CRP and ESR levels were higher in amyloidosis patients compared to controls (p<0.05). However, no correlations were found between CRP, ESR and SF-A levels in our patients (p>0.05).
In a study by Zhan et al. (31), it was determined that SF-A levels decreased in parallel with the decrease in eGFR levels of CKD patients. Similarly, our study showed that SF-A levels were lower in patients with eGFR values below 30 mL/min/1.73 m2 compared to those with eGFR values between 30-60 mL/min/1.73 m2 (p=0.011). However, we found no association between SF-A levels and eGFR values in AA amyloidosis patients (r=0.186, p=0.144).
A study by Shouman et al. (32), which investigated SF-A levels in hemodialysis patients, showed that pre-dialysis SF-A levels were higher in pediatric hemodialysis patients compared to healthy subjects. Furthermore, they showed a significant decrease in SF-A levels after a single session of hemodialysis (33). In another study by Kirkpantur et al. (34), SF-A levels were reported to be associated with coronary artery calcification and the bone mineral density of recipients of maintenance hemodialysis. On the other hand, Lin et al. (35) found that increased calcium, decreased PTH and albumin levels were associated with the decrease in SF-A levels observed in hemodialysis patients. Similarly, the current study showed a positive correlation between calcium levels and SF-A levels (r=0.351, p=0.005), and a negative correlation between PTH levels and SF-A levels in patients with AA amyloidosis (r=0.325, p=0.019).
We believe that the findings of our study contribute to the literature in terms of clarifying the role of SF-A in AA amyloidosis.
Our findings should be interpreted in the context of several limitations. We acknowledge that the small number of AA amyloidosis patients in our study is a limitation. Further, all subjects were from a single center; therefore, it is apparent that future multi-centered studies with a higher number of patients are required to confirm our results. Finally, this study is cross-sectional in design, and did not employ prospective follow-up. As such, the relationships shown in this study should not be considered to show causality.
CONCLUSION
Our study showed that there were no differences between patients with AA amyloidosis and healthy controls in terms of SF-A levels, and no correlations were found between carotid IMT and SF-A levels in patients with AA amyloidosis. However, higher SF-A levels were associated with higher calcium and albumin levels, while SF-A levels were also negatively correlated with PTH levels. In addition, SF-A levels of AA amyloidosis patients with eGFR <30 mL/min/1.73 m2 were found to be lower than that of patients with eGFR values between 30-60 mL/min/1.73 m2. Additional studies are required to investigate the relationship between SF-A levels and carotid IMT, and to clarify the possible role of SF-A in AA amyloidosis.